Vistagen Therapeutics, Inc. Income Statement
VTGN|8 years of annual SEC 10-K data (FY2011-FY2023)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Vistagen Therapeutics, Inc. reported $1M in revenue and $48M in net loss for FY2023. Revenue has declined at a 5.1% compound annual rate over the past 12 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 | FY2022 | FY2021 | FY2018 | FY2017 | FY2014 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $354.0K | $0 | $1.3M | $0 | $200.4K | $1.3M | $2.1M |
| SG&A Expense | $13.5M | $7.1M | $7.4M | $6.3M | $13.9M | $3.6M | $5.0M | $5.0M |
| R&D Expense | $35.4M | $11.9M | $13.4M | $5.2M | $3.9M | $3.4M | $5.4M | $3.7M |
| Operating Income | -$47.8M | -$17.9M | -$20.8M | -$10.2M | -$17.9M | -$6.8M | -$9.0M | -$6.6M |
| Interest Expense | $19.9K | $1.6K | $30.1K | $4.6K | $770.8K | -$920.7K | -$1.9M | $3.1M |
| Income Tax | $3.4K | $2.6K | $2.6K | $2.4K | $2.3K | $3.7K | $1.6K | $1.6K |
| Net Income | -$47.8M | -$17.9M | -$20.8M | -$10.3M | -$47.2M | -$42.7M | -$230.9K | -$230.9K |
| EPS (Basic) | -$7.38 | -$0.49 | - | - | - | -$1.27 | - | - |
| EPS (Diluted) | - | - | -$0.50 | -$1.54 | -$29.08 | -$1.27 | -$0.83 | -$1.81 |
| Shares Outstanding | - | - | 42.6M | 5.1M | 1.6M | 18.1M | 11.1M | 5.2M |
| Operating Margin | -4308.3% | -5066.1% | - | -819.9% | - | -3389.8% | -673.8% | -317.0% |
| Profit Margin | -4306.8% | -5066.2% | - | -820.4% | - | -21315.0% | -17.2% | -11.2% |